APA (7th ed.) Citation

R, S., WR, W., P, H., 3rd, P. J., LE, P., L, T., . . . J, D. (2024). Vosoritide therapy in children with achondroplasia aged 3-59 months: A multinational, randomised, double-blind, placebo-controlled, phase 2 trial. The Lancet. Child & adolescent health, 8(1), 40. https://doi.org/10.1016/S2352-4642(23)00265-1

Chicago Style (17th ed.) Citation

R, Savarirayan, et al. "Vosoritide Therapy in Children with Achondroplasia Aged 3-59 Months: A Multinational, Randomised, Double-blind, Placebo-controlled, Phase 2 Trial." The Lancet. Child & Adolescent Health 8, no. 1 (2024): 40. https://doi.org/10.1016/S2352-4642(23)00265-1.

MLA (9th ed.) Citation

R, Savarirayan, et al. "Vosoritide Therapy in Children with Achondroplasia Aged 3-59 Months: A Multinational, Randomised, Double-blind, Placebo-controlled, Phase 2 Trial." The Lancet. Child & Adolescent Health, vol. 8, no. 1, 2024, p. 40, https://doi.org/10.1016/S2352-4642(23)00265-1.